| 000 | 01850 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517065348.0 | ||
| 264 | 0 | _c20161017 | |
| 008 | 201610s 0 0 eng d | ||
| 022 | _a1873-2364 | ||
| 024 | 7 |
_a10.1016/j.nmd.2015.11.001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJohannsen, Stephan | |
| 245 | 0 | 0 |
_aFunctional characterization of the RYR1 mutation p.Arg4737Trp associated with susceptibility to malignant hyperthermia. _h[electronic resource] |
| 260 |
_bNeuromuscular disorders : NMD _cJan 2016 |
||
| 300 |
_a21-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAnesthetics _xpharmacology |
| 650 | 0 | 4 |
_aArginine _xgenetics |
| 650 | 0 | 4 |
_aB-Lymphocytes _xdrug effects |
| 650 | 0 | 4 |
_aCaffeine _xpharmacology |
| 650 | 0 | 4 | _aCell Line, Transformed |
| 650 | 0 | 4 |
_aCresols _xpharmacology |
| 650 | 0 | 4 | _aFamily Health |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFungicides, Industrial _xpharmacology |
| 650 | 0 | 4 |
_aGenetic Predisposition to Disease _xgenetics |
| 650 | 0 | 4 | _aGermany |
| 650 | 0 | 4 |
_aHalothane _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMalignant Hyperthermia _xgenetics |
| 650 | 0 | 4 |
_aMuscle Contraction _xdrug effects |
| 650 | 0 | 4 |
_aMuscle, Skeletal _xdrug effects |
| 650 | 0 | 4 |
_aPhosphodiesterase Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aPolymorphism, Single Nucleotide _xgenetics |
| 650 | 0 | 4 |
_aRyanodine Receptor Calcium Release Channel _xgenetics |
| 650 | 0 | 4 |
_aTryptophan _xgenetics |
| 700 | 1 | _aTreves, Susan | |
| 700 | 1 | _aMüller, Clemens R | |
| 700 | 1 | _aMögele, Susanne | |
| 700 | 1 | _aSchneiderbanger, Daniel | |
| 700 | 1 | _aRoewer, Norbert | |
| 700 | 1 | _aSchuster, Frank | |
| 773 | 0 |
_tNeuromuscular disorders : NMD _gvol. 26 _gno. 1 _gp. 21-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.nmd.2015.11.001 _zAvailable from publisher's website |
| 999 |
_c25508965 _d25508965 |
||